ZLDPF (Zealand Pharma AS) Short Interest


ZLDPF Zealand Pharma AS ZLDPF
62 GF Score
Price $42.89
GF Value $1,948.90
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ZLDPF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Short Interest falls into.


ZLDPF
62GF Score
Zealand Pharma AS ZLDPF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (ZLDPF) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of $42.89 is trading 97.8% below its estimated GF Value™ of $1,948.90. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for ZLDPF:

  • Short Interest:
  • GF Value™: $1,948.90 vs. price of $42.89 (97.8% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the ZLDPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
62GF Score

Get the complete analysis for ZLDPF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.89
Price
$1,948.90
GF Value